多囊性卵巢症候群治疗市场 - 依治疗类型（药物[药物类别（口服避孕药、抗雄性激素）配销通路]、手术[卵巢楔形切除术、腹腔镜卵巢钻孔]）及全球预测，2024年至2032年

在全球 PCOS 盛行率不断上升的推动下，2024 年至 2032 年全球多囊性卵巢症候群治疗市场的复合年增长率将超过 5.8%。人们对这种疾病及其併发症的认识不断提高，促使更多女性寻求医疗干预。

已开发国家和新兴国家医疗保健预算的增加正在加强多囊性卵巢症候群先进治疗和诊断工具的取得。在此背景下，2023年4月，辉凌製药与生物创新研究院（BII）宣布建立策略伙伴关係，共同推动女性健康领域的创新。此次合作旨在支持和资助生殖医学领域的早期新创企业，解决女性特定病症的资金不足问题。

此外，增加的投资支持医疗研发，带来更好的诊断工具和更有效的治疗选择。改善的医疗基础设施和更多的财政资源有助于更好地早期发现和管理多囊性卵巢综合症，满足对综合治疗解决方案不断增长的需求。

整体多囊性卵巢症候群治疗市场根据治疗类型和地区进行分类。

由于人们越来越认识到手术介入是治疗严重病例的有效解决方案，手术细分市场预计到 2032 年将实现良好成长。由于非侵入性治疗有时效果不佳，特别是对于有明显症状或併发症的女性，手术选择可以提供更直接和实际的缓解。微创手术技术的创新改善了患者的治疗效果并缩短了恢復时间，使手术成为多囊性卵巢症候群治疗更可行的选择。

到 2032 年，选择性雌激素受体调节剂 (SERM) 药物类药物细分市场将占据重要的产业份额，因为它们能够有效解决与疾病相关的多种症状。 SERM，例如克罗米芬柠檬酸盐，广泛用于诱导多囊性卵巢症候群女性排卵，从而改善生育结果。它们选择性调节雌激素受体的能力有助于平衡荷尔蒙水平，降低子宫内膜增生的风险，并减轻月经週期不规则和多毛症等症状。此外，相对于手术干预，人们越来越偏好非侵入性药物治疗方案，这增强了它们的吸引力。

由于意识的提高和诊断实践的改进，欧洲多囊性卵巢症候群治疗市场规模将在预测期内显着扩大。公共卫生措施和教育活动的增加使人们对多囊性卵巢症候群有了更深入的了解，促使更多的人寻求治疗。此外，该地区的医疗保健系统专注于改善生殖健康并提供全面的护理选择。先进医疗技术和支持性医疗政策的可用性将促进欧洲各地获得有效的多囊性卵巢症候群治疗，从而增加市场价值。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 育龄妇女 PCOS 发生率上升
    • 提高认识和诊断
    • 政府和非政府组织的支持
    • 肥胖和久坐生活方式的发生率上升
  • 产业陷阱与挑战
    • 药物的副作用
    • 治疗费用高
• 成长潜力分析
• 监管环境
  • 我们
  • 欧洲
  • 亚太地区
• 管道分析
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

• 主要趋势
• 药物
  • 按药物类别
    • 口服避孕药
    • 抗雄激素
    • 胰岛素增敏剂
    • 抗忧郁药
    • 抗肥胖
    • 选择性雌激素受体调节剂 (SERM)
    • 其他药物类别
  • 按配销通路
    • 医院药房
    • 零售药局
    • 网路药局
• 手术
  • 卵巢楔形切除术
  • 腹腔镜卵巢打孔术
  • 其他手术

第 6 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 7 章：公司简介

• Abbott Laboratories
• AbbVie Plc
• Addex Therapeutics Ltd.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myer Squibb Company
• Ferring BV
• Johnson and Johnson
• Merck KGaA
• Mylan N.V
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Limited

Global Polycystic Ovarian Syndrome Treatment Market will show over 5.8% CAGR from 2024 to 2032, driven by increasing prevalence of PCOS globally. Rising awareness about the condition and its complications is prompting more women to seek medical intervention.

The increased healthcare budgets in developed and emerging countries are strengthening access to advanced treatments and diagnostic tools for PCOS. Against this backdrop, in April 2023, Ferring Pharmaceuticals and the BioInnovation Institute (BII) announced a strategic partnership to boost innovation in women's health. This collaboration aims to support and fund early-stage start-ups in reproductive medicine, addressing the underfunding of female-specific conditions.

Further, the augmented investments support medical R&D, leading to better diagnostic tools and more effective treatment options. The improved healthcare infrastructure and greater financial resources contribute to better early detection and management of PCOS, catering to the growing demand for comprehensive treatment solutions.

The overall polycystic ovarian syndrome treatment market is classified based on treatment type and region.

The surgery segment is set for decent growth through 2032, owing to the growing recognition of surgical interventions as effective solutions for severe cases. As non-invasive treatments sometimes fall short, especially for women with significant symptoms or complications, surgical options provide more immediate and tangible relief. The innovations in minimally invasive surgical techniques have improved patient outcomes and recovery times, making surgery a more viable option for PCOS management.

The Selective Estrogen Receptor Modulators (SERMs) drug class medication segment will hold significant industry share by 2032, due to their efficacy in addressing multiple symptoms associated with the condition. SERMs, such as clomiphene citrate, are widely used to induce ovulation in women with PCOS, thus improving fertility outcomes. Their ability to modulate estrogen receptors selectively helps in balancing hormone levels, reducing the risk of endometrial hyperplasia, and alleviating symptoms like irregular menstrual cycles and hirsutism. Moreover, the growing preference for non-invasive and pharmacological treatment options over surgical interventions enhances their appeal.

Europe polycystic ovarian syndrome treatment market size will expand at a notable pace during the forecast period, due to heightened awareness and better diagnostic practices. The increased public health initiatives and educational campaigns have led to greater understanding of PCOS, driving more individuals to seek treatment. Additionally, the healthcare system in the region focuses on improving reproductive health and offers comprehensive care options. The availability of advanced medical technologies and supportive medical policies will facilitate access to effective PCOS treatments across Europe, adding to market value.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of PCOS among women of reproductive age
    • 3.2.1.2 Rising awareness and diagnosis
    • 3.2.1.3 Support from government and non-governmental organizations
    • 3.2.1.4 Rising incidence of obesity and sedentary lifestyle
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects of medication
    • 3.2.2.2 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Medications
  • 5.2.1 By drug class
    • 5.2.1.1 Oral contraceptives
    • 5.2.1.2 Antiandrogen
    • 5.2.1.3 Insulin-sensitizing agents
    • 5.2.1.4 Antidepressants
    • 5.2.1.5 Anti-obesity
    • 5.2.1.6 Selective Estrogen Receptor Modulators (SERMs)
    • 5.2.1.7 Other drug classes
  • 5.2.2 By distribution channel
    • 5.2.2.1 Hospital pharmacies
    • 5.2.2.2 Retail pharmacies
    • 5.2.2.3 Online pharmacies
• 5.3 Surgery
  • 5.3.1 Ovarian wedge resection
  • 5.3.2 Laparoscopic ovarian drilling
  • 5.3.3 Other surgeries

Chapter 6 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 North America
  • 6.2.1 U.S.
  • 6.2.2 Canada
• 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 UK
  • 6.3.3 France
  • 6.3.4 Spain
  • 6.3.5 Italy
  • 6.3.6 Netherlands
  • 6.3.7 Rest of Europe
• 6.4 Asia Pacific
  • 6.4.1 China
  • 6.4.2 Japan
  • 6.4.3 India
  • 6.4.4 Australia
  • 6.4.5 South Korea
  • 6.4.6 Rest of Asia Pacific
• 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Mexico
  • 6.5.3 Rest of Latin America
• 6.6 Middle East and Africa
  • 6.6.1 South Africa
  • 6.6.2 Saudi Arabia
  • 6.6.3 UAE
  • 6.6.4 Rest of Middle East and Africa

Chapter 7 Company Profiles

• 7.1 Abbott Laboratories
• 7.2 AbbVie Plc
• 7.3 Addex Therapeutics Ltd.
• 7.4 AstraZeneca PLC
• 7.5 Bayer AG
• 7.6 Bristol-Myer Squibb Company
• 7.7 Ferring BV
• 7.8 Johnson and Johnson
• 7.9 Merck KGaA
• 7.10 Mylan N.V
• 7.11 Novartis AG
• 7.12 Pfizer Inc.
• 7.13 Sanofi SA
• 7.14 Takeda Pharmaceutical Company Limited
• 7.15 Teva Pharmaceutical Industries Limited